NASDAQ:APDN - Nasdaq - US03815U5083 - Common Stock - Currency: USD
0.5803
-0.02 (-2.8%)
The current stock price of APDN is 0.5803 USD. In the past month the price decreased by -32.82%. In the past year, price decreased by -99.42%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 18.19 | 150.35B | ||
DHR | DANAHER CORP | 25.08 | 133.69B | ||
A | AGILENT TECHNOLOGIES INC | 20.51 | 31.05B | ||
IQV | IQVIA HOLDINGS INC | 12.15 | 24.21B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 28.01 | 23.62B | ||
WAT | WATERS CORP | 29.17 | 20.67B | ||
WST | WEST PHARMACEUTICAL SERVICES | 31.47 | 15.01B | ||
ILMN | ILLUMINA INC | 23.83 | 12.56B | ||
RVTY | REVVITY INC | 18.22 | 10.79B | ||
ICLR | ICON PLC | 9.23 | 10.45B | ||
TEM | TEMPUS AI INC | N/A | 10.06B | ||
QGEN | QIAGEN N.V. | 18.4 | 9.15B |
Applied DNA Sciences, Inc. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. The company is headquartered in Stony Brook, New York and currently employs 46 full-time employees. The company went IPO on 2001-08-24. The firm is engaged in developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The firm operates through three segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. Therapeutic DNA Production Services segment operations consist of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, the development and sale of a proprietary RNAP for use in the production of messenger RNA (mRNA) therapeutics. MDx Testing Service segment operations consist of performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. DNA Tagging and Security Products and Services segment operations consist of the manufacture and detection of DNA for industrial supply chains and security services.
APPLIED DNA SCIENCES INC
50 Health Sciences Drive
Stony Brook NEW YORK 11790 US
CEO: James A. Hayward
Employees: 47
Phone: 16312408800
The current stock price of APDN is 0.5803 USD. The price decreased by -2.8% in the last trading session.
The exchange symbol of APPLIED DNA SCIENCES INC is APDN and it is listed on the Nasdaq exchange.
APDN stock is listed on the Nasdaq exchange.
APPLIED DNA SCIENCES INC (APDN) has a market capitalization of 3.77M USD. This makes APDN a Nano Cap stock.
APPLIED DNA SCIENCES INC (APDN) currently has 47 employees.
The Revenue of APPLIED DNA SCIENCES INC (APDN) is expected to grow by 50.26% in the next year. Check the estimates tab for more information on the APDN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
APDN does not pay a dividend.
APPLIED DNA SCIENCES INC (APDN) will report earnings on 2025-08-06.
APPLIED DNA SCIENCES INC (APDN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-286).
The outstanding short interest for APPLIED DNA SCIENCES INC (APDN) is 7.79% of its float. Check the ownership tab for more information on the APDN short interest.
ChartMill assigns a fundamental rating of 3 / 10 to APDN. APDN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months APDN reported a non-GAAP Earnings per Share(EPS) of -286. The EPS increased by 47.04% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -147.7% | ||
ROE | -184.96% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 43% to APDN. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 92.97% and a revenue growth 50.26% for APDN